Esra Demir Unal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Esra Demir Unal has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Selim Selçuk Çomoğlu
Ankara Etlik Şehir Hastanesi, Nöroloji Kliniği, Ankara, Türkiye
3 shared publications - Funda Eren
Department of Biochemistry , Ankara Bilkent City Hospital , Ankara , Türkiye
2 shared publications - Gönül Vural
Department of Neurology, Faculty of Medicine, Ankara Yıldırım Beyazıt University, Ankara 06800, Türkiye
2 shared publications - Salim Neselioglu
Department of Biochemistry , Ankara Bilkent City Hospital , Ankara , Türkiye
2 shared publications - Özcan Erel
Department of Medical Biochemistry, Ankara Bilkent City Hospital, 06800 Ankara, Turkey
2 shared publications - Agnes Langer
Department of Neurology, Medical University of Vienna, Vienna, Austria
1 shared publication
Latest Publications
- 6 November 2026
- Published by Taylor & Francis
- p. 128-134
Crossing Pathways between Sleep Disorders and Neurodegenerative Disorders
- 6 November 2026
- Published by Taylor & Francis
- p. 128-134
Crossing Pathways between Sleep Disorders and Neurodegenerative Disorders
- 1 October 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 153
Punding induced by continuous subcutaneous foslevodopa/foscarbidopa infusion in atypical parkinsonism
- 1 October 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 153
Punding induced by continuous subcutaneous foslevodopa/foscarbidopa infusion in atypical parkinsonism
- Open Access
- 29 July 2026
- Published by Baycinar Tibbi Yayincilik in Journal of Parkinson’s Disease and Movement Disorders
- Vol. 29 (2) , 76-80
Acetazolamide-associated lingual myokymia: A reversible peripheral nerve hyperexcitability phenotype
Myokymia is a motor phenomenon within the spectrum of peripheral nerve hyperexcitability, characterized by fine, rhythmic, and often sustained involuntary muscle contractions. Clinically, it manifests as superficial undulation or “rippling” and is defined electromyographically by brief, grouped motor unit discharges. This case report presents a 23-year-old female with idiopathic intracranial hypertension who developed clinically isolated lingual myokymia shortly after the initiation of acetazolamide therapy. The diagnosis of lingual myokymia was confirmed by characteristic spontaneous, grouped motor unit discharges on genioglossus needle electromyography. To the best of our knowledge, this is the first detailed case of acetazolamide-related lingual myokymia reported from Türkiye, and it aims to contribute to the differential diagnosis of drug-induced focal peripheral nerve hyperexcitability.
- 29 July 2026
- Published by Baycinar Tibbi Yayincilik in Journal of Parkinson’s Disease and Movement Disorders
- Vol. 29 (2) , 76-80
Open AccessAcetazolamide-associated lingual myokymia: A reversible peripheral nerve hyperexcitability phenotype
Myokymia is a motor phenomenon within the spectrum of peripheral nerve hyperexcitability, characterized by fine, rhythmic, and often sustained involuntary muscle contractions. Clinically, it manifests as superficial undulation or “rippling” and is defined electromyographically by brief, grouped motor unit discharges. This case report presents a 23-year-old female with idiopathic intracranial hypertension who developed clinically isolated lingual myokymia shortly after the initiation of acetazolamide therapy. The diagnosis of lingual myokymia was confirmed by characteristic spontaneous, grouped motor unit discharges on genioglossus needle electromyography. To the best of our knowledge, this is the first detailed case of acetazolamide-related lingual myokymia reported from Türkiye, and it aims to contribute to the differential diagnosis of drug-induced focal peripheral nerve hyperexcitability.
- Open Access
- 29 July 2026
- Published by Baycinar Tibbi Yayincilik in Journal of Parkinson’s Disease and Movement Disorders
- Vol. 29 (2) , 33-45
The molecular and genetic view of tauopathies: From structural polymorphism to systemic neurodegeneration
Tauopathies constitute a broad group of clinically heterogeneous neurodegenerative disorders, including Alzheimer’s disease, progressive supranuclear palsy, and Pick’s disease, characterized by abnormal metabolism, misfolding, and intracellular aggregation of the microtubule-associated protein tau. These diseases are defined by disruptions in alternative splicing of the tau protein, toxic post-translational modifications such as hyperphosphorylation and acetylation, and the “prion-like” spread of pathological tau seeds across anatomically connected regions. Recent cryogenic electron microscopy studies have demonstrated that each tauopathy has a unique filament-folding structure, elucidating the molecular basis of phenotypic variation among diseases. The aim of this review is to provide a holistic perspective by synthesizing recent developments in the molecular and genetic architecture of tauopathies, particularly newly discovered genetic risk loci and cellular proteostasis mechanisms. In this context, detailing the process from the physiological functions of the tau protein to its pathological transformation aims to analytically evaluate the diagnostic value of fluid biomarkers and current data on next-generation clinical-stage therapeutic strategies, such as monoclonal antibodies and antisense oligonucleotides.
- 29 July 2026
- Published by Baycinar Tibbi Yayincilik in Journal of Parkinson’s Disease and Movement Disorders
- Vol. 29 (2) , 33-45
Open AccessThe molecular and genetic view of tauopathies: From structural polymorphism to systemic neurodegeneration
Tauopathies constitute a broad group of clinically heterogeneous neurodegenerative disorders, including Alzheimer’s disease, progressive supranuclear palsy, and Pick’s disease, characterized by abnormal metabolism, misfolding, and intracellular aggregation of the microtubule-associated protein tau. These diseases are defined by disruptions in alternative splicing of the tau protein, toxic post-translational modifications such as hyperphosphorylation and acetylation, and the “prion-like” spread of pathological tau seeds across anatomically connected regions. Recent cryogenic electron microscopy studies have demonstrated that each tauopathy has a unique filament-folding structure, elucidating the molecular basis of phenotypic variation among diseases. The aim of this review is to provide a holistic perspective by synthesizing recent developments in the molecular and genetic architecture of tauopathies, particularly newly discovered genetic risk loci and cellular proteostasis mechanisms. In this context, detailing the process from the physiological functions of the tau protein to its pathological transformation aims to analytically evaluate the diagnostic value of fluid biomarkers and current data on next-generation clinical-stage therapeutic strategies, such as monoclonal antibodies and antisense oligonucleotides.
- Open Access
- 27 March 2026
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 7 (2) , 313-322
Explainable multimodal imaging–based machine learning for cardiovascular risk stratification in early Parkinson’s disease
Aims: This study aimed to characterize convergent biochemical and cardiovascular imaging endophenotypes of atherosclerotic risk in early PD and to implement an interpretable machine-learning architecture integrating multimodal clinical and imaging parameters for precision cardiovascular risk profiling and cardiometabolic classification. Methods: A total of 125 early-stage idiopathic PD patients and age- and sex-matched controls were analyzed. Feature space was reduced using cross-validated Least Absolute Shrinkage and Selection Operator (LASSO) with penalty tuning and stability selection to mitigate multicollinearity. XGBoost, Random Forest, RBF-kernel Support Vector Machine, and Stochastic Gradient Boosting models were trained under a train–hold-out framework with Bayesian hyperparameter optimization. Model performance was assessed via bootstrapping, and interpretability was provided using SHapley Additive exPlanations (SHAP). Results: PD patients showed increased hypertension (54.4%; OR 3.2, p=0.007) and hypercholesterolemia (OR 2.8, p=0.01), with excess left ventricular systolic dysfunction (28.8% vs 0%, p
- 27 March 2026
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 7 (2) , 313-322
Open AccessExplainable multimodal imaging–based machine learning for cardiovascular risk stratification in early Parkinson’s disease
Aims: This study aimed to characterize convergent biochemical and cardiovascular imaging endophenotypes of atherosclerotic risk in early PD and to implement an interpretable machine-learning architecture integrating multimodal clinical and imaging parameters for precision cardiovascular risk profiling and cardiometabolic classification. Methods: A total of 125 early-stage idiopathic PD patients and age- and sex-matched controls were analyzed. Feature space was reduced using cross-validated Least Absolute Shrinkage and Selection Operator (LASSO) with penalty tuning and stability selection to mitigate multicollinearity. XGBoost, Random Forest, RBF-kernel Support Vector Machine, and Stochastic Gradient Boosting models were trained under a train–hold-out framework with Bayesian hyperparameter optimization. Model performance was assessed via bootstrapping, and interpretability was provided using SHapley Additive exPlanations (SHAP). Results: PD patients showed increased hypertension (54.4%; OR 3.2, p=0.007) and hypercholesterolemia (OR 2.8, p=0.01), with excess left ventricular systolic dysfunction (28.8% vs 0%, p
- Open Access
- 16 March 2026
- Published by Baycinar Tibbi Yayincilik in Journal of Parkinson’s Disease and Movement Disorders
- Vol. 29 (1) , 22-25
Early axial involvement in progressive supranuclear palsy with progressive gait freezing: A rare case report
Progressive supranuclear palsy with progressive gait freezing (PSP-PGF) phenotype represents a unique presentation pattern emerging with selective involvement of axial locomotor networks in the early stages, where clinical findings may manifest before structural imaging biomarkers become evident. This case report presents a 68-year-old male patient unresponsive to standard levodopa therapy, characterized by a two-year insidious and progressive course of recurrent and complete blockages in gait initiation, a tendency toward retropulsion, and marked axial rigidity, while limb parkinsonism remained minimal and tremor was absent. This case emphasizes the importance of differential diagnosis in PSP cases presenting with early-onset predominant freezing of gait.
- 16 March 2026
- Published by Baycinar Tibbi Yayincilik in Journal of Parkinson’s Disease and Movement Disorders
- Vol. 29 (1) , 22-25
Open AccessEarly axial involvement in progressive supranuclear palsy with progressive gait freezing: A rare case report
Progressive supranuclear palsy with progressive gait freezing (PSP-PGF) phenotype represents a unique presentation pattern emerging with selective involvement of axial locomotor networks in the early stages, where clinical findings may manifest before structural imaging biomarkers become evident. This case report presents a 68-year-old male patient unresponsive to standard levodopa therapy, characterized by a two-year insidious and progressive course of recurrent and complete blockages in gait initiation, a tendency toward retropulsion, and marked axial rigidity, while limb parkinsonism remained minimal and tremor was absent. This case emphasizes the importance of differential diagnosis in PSP cases presenting with early-onset predominant freezing of gait.
- Open Access
- 1 March 2026
- Published by Turk Noroloji Dernegi in Turkish Journal Of Neurology
- Vol. 32 (1) , 75-83
Global infodemiological trends in Parkinson’s disease-associated sleep disorders: Long-term digital impact of the COVID-19 pandemic
Objectives: This study aimed to characterize global and regional information-seeking patterns for common Parkinson’s disease (PD)-related sleep disorders (SDs) and to assess whether the COVID-19 (coronavirus disease 2019) pandemic caused a permanent structural change in these patterns using interrupted time series analysis. Materials and methods: In this retrospective, multi-country infodemiological study, Google Trends monthly relative search volume data for 10 PD-related SDs was analyzed across nine countries and globally between 2015 and 2025. Relative search volumes were deseasonalized, and prepandemic (March 1, 2015–February 29, 2020) and postpandemic (March 1, 2020–February 28, 2025) periods were compared using a t-test or Mann-Whitney U test, as appropriate, and 95% confidence intervals were estimated by bootstrap. Data extraction used Python pytrends. Interrupted time series regression modeled level (β2) and slope (β3) changes, with Newey-West corrections for autocorrelation when required. Results: Globally, insomnia relative search volume increased from 42.5 ± 5.2 to 68.2 ± 8.4 ( p < 0.001). Rapid eye movement sleep behavior disorder (RBD) searches rose by 52.1% (mean difference: +6.3; 95% confidence interval, 4.8-7.9). Interrupted time series showed immediate level increases for insomnia (β2 = +12.4, p < 0.001) and excessive daytime sleepiness (β2 = +4.2, p = 0.021), and a significant positive slope acceleration in RBD (β3 = +0.08, p = 0.045). Türkiye demonstrated an accelerated restless leg syndrome slope (β3 = +0.45, p < 0.01). Conclusion: The COVID-19 pandemic produced a lasting digital phenotypic shift in PD-related SDs, with notable global increases in insomnia and RBD interest, and region-specific rises, such as restless leg syndrome in Türkiye. Infodemiology offers valuable epidemiological surveillance insights to guide clinical and public health responses.
- 1 March 2026
- Published by Turk Noroloji Dernegi in Turkish Journal Of Neurology
- Vol. 32 (1) , 75-83
Open AccessGlobal infodemiological trends in Parkinson’s disease-associated sleep disorders: Long-term digital impact of the COVID-19 pandemic
Objectives: This study aimed to characterize global and regional information-seeking patterns for common Parkinson’s disease (PD)-related sleep disorders (SDs) and to assess whether the COVID-19 (coronavirus disease 2019) pandemic caused a permanent structural change in these patterns using interrupted time series analysis. Materials and methods: In this retrospective, multi-country infodemiological study, Google Trends monthly relative search volume data for 10 PD-related SDs was analyzed across nine countries and globally between 2015 and 2025. Relative search volumes were deseasonalized, and prepandemic (March 1, 2015–February 29, 2020) and postpandemic (March 1, 2020–February 28, 2025) periods were compared using a t-test or Mann-Whitney U test, as appropriate, and 95% confidence intervals were estimated by bootstrap. Data extraction used Python pytrends. Interrupted time series regression modeled level (β2) and slope (β3) changes, with Newey-West corrections for autocorrelation when required. Results: Globally, insomnia relative search volume increased from 42.5 ± 5.2 to 68.2 ± 8.4 ( p < 0.001). Rapid eye movement sleep behavior disorder (RBD) searches rose by 52.1% (mean difference: +6.3; 95% confidence interval, 4.8-7.9). Interrupted time series showed immediate level increases for insomnia (β2 = +12.4, p < 0.001) and excessive daytime sleepiness (β2 = +4.2, p = 0.021), and a significant positive slope acceleration in RBD (β3 = +0.08, p = 0.045). Türkiye demonstrated an accelerated restless leg syndrome slope (β3 = +0.45, p < 0.01). Conclusion: The COVID-19 pandemic produced a lasting digital phenotypic shift in PD-related SDs, with notable global increases in insomnia and RBD interest, and region-specific rises, such as restless leg syndrome in Türkiye. Infodemiology offers valuable epidemiological surveillance insights to guide clinical and public health responses.
- 1 January 2026
- Published by Turk Noropsikiyatri Dernegi in Archives of Neuropsychiatry
- Vol. 63, 333-340
Therapeutic Spectrum of Intermittent Apomorphine in Parkinson’s Disease: Neuropsychiatric, Behavioral, and Cognitive Analyses
Intermittent subcutaneous (SC) apomorphine is a fast-acting dopamine agonist used in the management of motor fluctuations in advanced Parkinson’s disease (PD). While its motor benefits are well established the effects on non-motor domains and the modifying role of chronological age remain less certain. This prospective observational study aimed to evaluate the effectiveness of intermittent SC apomorphine on motor and non-motor outcomes in idiopathic PD patients with persistent motor fluctuations despite optimized oral therapy, and to examine whether age influenced therapeutic response. Thirty-five idiopathic PD patients treated with intermittent SC apomorphine were followed for twelve weeks and assessed at baseline and week 12. Motor outcomes included Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part III and diary-based daily “off” and “on” time without dyskinesia. Non-motor outcomes comprised the Montreal Cognitive Assessment (MoCA), Beck Depression Inventory (BDI), Parkinson’s Disease Questionnaire (PDQ-8), and Parkinson’s Disease Sleep Scale (PDSS). Subgroup analyses compared outcomes between patients aged <45 and ≥45 years and interaction effects were explored. MDS-UPDRS Part III scores improved from 45.71 (SD 11.93) to 29.86 (SD 12.24) (p <0.001). Mean daily “off” time decreased from 5.60 (1.65) to 2.26 (0.95) hours, while “on” time without dyskinesia raise from 10.34 (1.76) to 13.89 (0.93) hours (both p <0.001). Non-motor outcomes also improved: BDI declined from 23.03 (5.70) to 18.09 (4.87), MoCA increased from 15.74 (5.51) to 18.03 (6.05), and PDQ-8 from 22.80 (5.60) to 17.54 (5.84) (all p <0.001). Parkinson’s disease sleep scale showed no significant change. No significant age-by-treatment interaction effects were detected. Intermittent subcutaneous apomorphine was associated with significant improvements in multidimensional aspects, including motor and various non-motor domains, which are closely related to cognition, mood, and quality of life in PD. Benefits were consistent across age groups, indicating chronological age does not influence efficacy.
- 1 January 2026
- Published by Turk Noropsikiyatri Dernegi in Archives of Neuropsychiatry
- Vol. 63, 333-340
Therapeutic Spectrum of Intermittent Apomorphine in Parkinson’s Disease: Neuropsychiatric, Behavioral, and Cognitive Analyses
Intermittent subcutaneous (SC) apomorphine is a fast-acting dopamine agonist used in the management of motor fluctuations in advanced Parkinson’s disease (PD). While its motor benefits are well established the effects on non-motor domains and the modifying role of chronological age remain less certain. This prospective observational study aimed to evaluate the effectiveness of intermittent SC apomorphine on motor and non-motor outcomes in idiopathic PD patients with persistent motor fluctuations despite optimized oral therapy, and to examine whether age influenced therapeutic response. Thirty-five idiopathic PD patients treated with intermittent SC apomorphine were followed for twelve weeks and assessed at baseline and week 12. Motor outcomes included Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part III and diary-based daily “off” and “on” time without dyskinesia. Non-motor outcomes comprised the Montreal Cognitive Assessment (MoCA), Beck Depression Inventory (BDI), Parkinson’s Disease Questionnaire (PDQ-8), and Parkinson’s Disease Sleep Scale (PDSS). Subgroup analyses compared outcomes between patients aged <45 and ≥45 years and interaction effects were explored. MDS-UPDRS Part III scores improved from 45.71 (SD 11.93) to 29.86 (SD 12.24) (p <0.001). Mean daily “off” time decreased from 5.60 (1.65) to 2.26 (0.95) hours, while “on” time without dyskinesia raise from 10.34 (1.76) to 13.89 (0.93) hours (both p <0.001). Non-motor outcomes also improved: BDI declined from 23.03 (5.70) to 18.09 (4.87), MoCA increased from 15.74 (5.51) to 18.03 (6.05), and PDQ-8 from 22.80 (5.60) to 17.54 (5.84) (all p <0.001). Parkinson’s disease sleep scale showed no significant change. No significant age-by-treatment interaction effects were detected. Intermittent subcutaneous apomorphine was associated with significant improvements in multidimensional aspects, including motor and various non-motor domains, which are closely related to cognition, mood, and quality of life in PD. Benefits were consistent across age groups, indicating chronological age does not influence efficacy.
- 25 December 2025
- Published by Adnan Menderes University in Meandros Medical and Dental Journal
- Vol. 26 (4) , 390-402
Comparative Prospective Analysis of Pharmacological Modalities in Alzheimer’s Disease
Objective: This study aimed to prospectively investigate the pharmaco-biological optimization of Alzheimer’s disease (AD) treatments in terms of psychocognitive and metabo-inflammatory aspects via multivariate correlation analyses. Methods: A 24-week pre-and-post-treatment follow-up study was conducted prospectively on AD patients. The effects of each pharmacological modality on psycho-cognitive (categorical and numeric)(Mini-Mental Status Examination (MMSE), Clinical Dementia Rating Scale (CDR)), Metabo-inflammatory, and hematologic indexes were analyzed. Results: The mild cognitive impairment (MCI) stage was lower in the standardized Ginkgo biloba extract (EGB-761) (median[Interquartile Range(IQR)]=1[4.0](χ2=15.610)) group compared to the other modalities in CDR analyses, whereas it was higher in the donepezil-memantine (9[36.0](χ2=11.469)). In MMSE analyses (categorical data), MCI patients were dominant (MMSE:21-26) in the donepezil group (median(IQR(17[68.0](χ2=7.946)), while moderate stage (MMSE score:11-20) was in memantine (18[69.2](χ2=9.489)) and donepezil-memantine (16[64.0](χ2=10.545)). The memantine group showed apparent anti-inflammatory effects in hematological and inflammatory indices. Metabolic disturbance regarding thyroid dysfunction was observed in the EGB 761 group. A positive correlation was detected between psycho-cognitive tests and platelet count (20.9% for CDR and 22.3% for MMSE). Conclusion: Donepezil showed superior performance in terms of cognitive improvement, and the combination of donepezil-memantine offers significant advantages, especially in cognitive-functional enhancement. Memantine showed significantly superior results in terms of anti-inflammatory effects; despite the need for careful monitoring of metabolic imbalances, it was demonstrated that EGB-761 can be considered as a monotherapy option in the treatment of MCI. The platelet indices can have an important place in both future research and clinical applications as advanced psychocognitive laboratory markers.
- 25 December 2025
- Published by Adnan Menderes University in Meandros Medical and Dental Journal
- Vol. 26 (4) , 390-402
Comparative Prospective Analysis of Pharmacological Modalities in Alzheimer’s Disease
Objective: This study aimed to prospectively investigate the pharmaco-biological optimization of Alzheimer’s disease (AD) treatments in terms of psychocognitive and metabo-inflammatory aspects via multivariate correlation analyses. Methods: A 24-week pre-and-post-treatment follow-up study was conducted prospectively on AD patients. The effects of each pharmacological modality on psycho-cognitive (categorical and numeric)(Mini-Mental Status Examination (MMSE), Clinical Dementia Rating Scale (CDR)), Metabo-inflammatory, and hematologic indexes were analyzed. Results: The mild cognitive impairment (MCI) stage was lower in the standardized Ginkgo biloba extract (EGB-761) (median[Interquartile Range(IQR)]=1[4.0](χ2=15.610)) group compared to the other modalities in CDR analyses, whereas it was higher in the donepezil-memantine (9[36.0](χ2=11.469)). In MMSE analyses (categorical data), MCI patients were dominant (MMSE:21-26) in the donepezil group (median(IQR(17[68.0](χ2=7.946)), while moderate stage (MMSE score:11-20) was in memantine (18[69.2](χ2=9.489)) and donepezil-memantine (16[64.0](χ2=10.545)). The memantine group showed apparent anti-inflammatory effects in hematological and inflammatory indices. Metabolic disturbance regarding thyroid dysfunction was observed in the EGB 761 group. A positive correlation was detected between psycho-cognitive tests and platelet count (20.9% for CDR and 22.3% for MMSE). Conclusion: Donepezil showed superior performance in terms of cognitive improvement, and the combination of donepezil-memantine offers significant advantages, especially in cognitive-functional enhancement. Memantine showed significantly superior results in terms of anti-inflammatory effects; despite the need for careful monitoring of metabolic imbalances, it was demonstrated that EGB-761 can be considered as a monotherapy option in the treatment of MCI. The platelet indices can have an important place in both future research and clinical applications as advanced psychocognitive laboratory markers.